Status:
COMPLETED
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
18+ years
Brief Summary
To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease
Eligibility Criteria
Inclusion
- Inclusion criteria;
- Patients diagnosed as Alzheimer's Disease by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to Functional Assessment Staging (FAST) score 4 or 5.
- Exclusion criteria;
- Patients who used Aricept within 3 months prior to dosing.
- Patients registered this survey before.
- Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
Exclusion
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 18 2016
Estimated Enrollment :
894 Patients enrolled
Trial Details
Trial ID
NCT01251718
Start Date
December 1 2010
End Date
February 18 2016
Last Update
July 24 2023
Active Locations (106)
Enter a location and click search to find clinical trials sorted by distance.
1
Anjo, Aichi-ken, Japan
2
Nagoya, Aichi-ken, Japan
3
Daisen, Akita, Japan
4
Hirosaki, Aomori, Japan